Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles

• Status: Terminated
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the fixed GnRH antagonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: V.K.V. American Hospital, Istanbul
• Treatments: Triptorelin Pamoate

Criteria

Inclusion Criteria:

• Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up and ICSI.

• Embryo transfer performed on day 3

Exclusion Criteria:

• Participation in another trial that was being conducted in our unit at the same time.

• Preimplantation genetic screening cycles.

• Day 5 embryo transfers.